Skip to main
GOSS

GOSS Stock Forecast & Price Target

GOSS Analyst Ratings

Based on 6 analyst ratings
Buy
Strong Buy 33%
Buy 33%
Hold 17%
Sell 17%
Strong Sell 0%

Bulls say

Gossamer Bio is supported by its strong partnership with Chiesi, a projected launch of Seralutinib in the second half of 2027, and positive support from KOLs who view PROSERA as a successful treatment under p<0.05 and are eager for another mechanism of action, and the potential for a differentiated inhaled TKI. While the recent debt restructuring may be dilutive, Gossamer's long-term financial viability is supported by its debt reduction and additional financings. Potential risks include clinical development and commercialization risks, pricing and reimbursement risks, and potential disruptions to clinical trials in Eastern Europe.

Bears say

Gossamer Bio is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics in the areas of immunology, inflammation, and oncology. However, the recent Phase 3 results for their lead candidate, seralutinib, failed to meet the primary endpoint of improved median change in 6-minute walk distance at 24 weeks, causing concern about the drug's potential for regulatory approval and commercial success. In addition, the company's existing convertible debt and potential need for additional financing also adds uncertainty to their financial future. Therefore, a neutral outlook is warranted until there is more clarity on the drug's potential and the company's financial situation.

GOSS has been analyzed by 6 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 33% recommend Buy, 17% suggest Holding, 17% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Gossamer Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Gossamer Bio Inc (GOSS) Forecast

Analysts have given GOSS a Buy based on their latest research and market trends.

According to 6 analysts, GOSS has a Buy consensus rating as of Aug 5, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $2.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $2.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Gossamer Bio Inc (GOSS)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.